Fortress Biotech Inc.(FBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

FBIO Fortress Biotech Inc.

休市中 03-27 16:00:00 EDT

2.76

-0.12

-4.17%

盘后2.70

-0.06-2.00%

19:42 EDT

最高2.89	最低2.71	成交量35.67万
今开2.89	昨收2.88	日振幅6.25%
总市值8,566万	流通市值6,489万	总股本3,104万
成交额99.11万	换手率1.52%	流通股本2,351万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"FBIO","market":"US","secType":"STK","nameCN":"Fortress Biotech Inc.","latestPrice":2.76,"timestamp":1774641600000,"preClose":2.88,"halted":0,"volume":356681,"hourTrading":{"tag":"盘后","latestPrice":2.7049,"preClose":2.76,"latestTime":"19:42 EDT","volume":3415,"amount":9536.58,"timestamp":1774654925914,"change":-0.0551,"changeRate":-0.019964,"amplitude":0.034457},"delay":0,"changeRate":-0.041666666666666706,"floatShares":23511081,"shares":31037937,"eps":-0.293,"marketStatus":"休市中","change":-0.12,"latestTime":"03-27 16:00:00 EDT","open":2.89,"high":2.89,"low":2.71,"amount":991137.315818,"amplitude":0.0625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.293,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.88,"preHourTrading":{"tag":"盘前","latestPrice":2.86,"preClose":2.88,"latestTime":"09:25 EDT","volume":859,"amount":2451.519857,"timestamp":1774617900055,"change":-0.02,"changeRate":-0.006944,"amplitude":0.027778},"postHourTrading":{"tag":"盘后","latestPrice":2.7049,"preClose":2.76,"latestTime":"19:42 EDT","volume":3415,"amount":9536.58,"timestamp":1774654925914,"change":-0.0551,"changeRate":-0.019964,"amplitude":0.034457},"volumeRatio":0.718286,"impliedVol":1.3073,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/FBIO","defaultTab":"news","newsList":[{"id":"1158636643","title":"Fortress Biotech子公司Cyprium Therapeutics达成协议 以2.05亿美元出售罕见儿科疾病优先审评券","url":"https://stock-news.laohu8.com/highlight/detail?id=1158636643","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158636643?lang=zh_cn&edition=full","pubTime":"2026-02-23 22:25","pubTimestamp":1771856715,"startTime":"0","endTime":"0","summary":"Fortress Biotech旗下子公司Cyprium Therapeutics近日签署重要协议，将其持有的罕见儿科疾病优先审评凭证以2.05亿美元价格售出。这项交易标志着生物制药领域资产货币化的典型案例。\n优先审评券制度由美国FDA设立，旨在激励药企研发针对罕见儿科疾病的创新疗法。持有者可通过该凭证加速其他新药上市审评流程。此次交易不仅为Cyprium带来可观现金流，更凸显出稀有监管资产在医药市场的巨大价值。\n随着全球医药监管环境持续优化，此类优先审评券已成为稀缺资源。本次交易金额创下同类资产转让的新高，预计将对生物科技行业的资产估值体系产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIO","BK4139"],"gpt_icon":0},{"id":"1155503909","title":"Fortress Biotech子公司Cyprium Therapeutics达成协议，以2.05亿美元出售罕见儿科疾病优先审评券","url":"https://stock-news.laohu8.com/highlight/detail?id=1155503909","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155503909?lang=zh_cn&edition=full","pubTime":"2026-02-23 21:31","pubTimestamp":1771853480,"startTime":"0","endTime":"0","summary":"Fortress Biotech Inc.（简称Fortress Biotech）旗下子公司Cyprium Therapeutics已签署一项协议，将旗下持有的罕见儿科疾病优先审评券以2.05亿美元的价格出售。该交易有望为Cyprium Therapeutics带来可观的资金流入，进一步增强其在罕见病治疗领域的研发实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIO","BK4139"],"gpt_icon":0},{"id":"1167862155","title":"Avenue Therapeutics与Atx-04达成全球独家授权协议，用于庞贝氏病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1167862155","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167862155?lang=zh_cn&edition=full","pubTime":"2026-02-23 21:02","pubTimestamp":1771851741,"startTime":"0","endTime":"0","summary":"Avenue Therapeutics, Inc. 已就Atx-04达成一项全球独家授权协议，该药物旨在治疗庞贝氏病。此次合作标志着公司在拓展其治疗产品线方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ATXI","BK4139","FBIO"],"gpt_icon":0},{"id":"1193858645","title":"Fortress Biotech与Cyprium Therapeutics宣布美国FDA批准Zycubo®（组氨酸铜），成为美国首个且唯一获批治疗门克斯病的疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1193858645","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193858645?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:46","pubTimestamp":1768308412,"startTime":"0","endTime":"0","summary":"Fortress Biotech Inc.与Cyprium Therapeutics联合宣布，其创新药物Zycubo®（组氨酸铜）已获得美国食品药品监督管理局（FDA）的正式批准。这一突破性疗法是美国境内首个且目前唯一获准用于治疗门克斯病的治疗方案，标志着罕见病治疗领域的一项重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBIO"],"gpt_icon":0},{"id":"1153698516","title":"Journey Medical Corporation公布评估Emrosi™ (Dfd-29)对健康成年人微生物群影响的临床试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1153698516","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153698516?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:31","pubTimestamp":1765373472,"startTime":"0","endTime":"0","summary":"Journey Medical Corporation公布了评估Emrosi™ (Dfd-29)对健康成年人微生物群影响的临床试验结果，结果已刊登在《皮肤病药物杂志》上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","FBIO","DERM"],"gpt_icon":0},{"id":"1115885695","title":"Fortress Biotech：Cyprium将在NDA批准后保留对任何PRV的所有权，并将获得版税以及高达1.29亿美元的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1115885695","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115885695?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:37","pubTimestamp":1763383035,"startTime":"0","endTime":"0","summary":"Fortress Biotech：Cyprium将在NDA批准后保留对任何PRV的所有权，并将获得版税以及高达1.29亿美元的里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIO","BK4139"],"gpt_icon":0},{"id":"1126564189","title":"Fortress Biotech Inc.：在11月14日，Sentynl通知Cyprium已重新提交Cutx-101的NDA给FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1126564189","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126564189?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:33","pubTimestamp":1763382814,"startTime":"0","endTime":"0","summary":"Fortress Biotech Inc.：在11月14日，Sentynl通知Cyprium已重新提交Cutx-101的NDA给FDA","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBIO"],"gpt_icon":0},{"id":"1130939272","title":"Fortress Biotech及其子公司Urica Therapeutics宣布Crystalys Therapeutics全球III期Dotinurad治疗痛风临床试验首位患者接受治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1130939272","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130939272?lang=zh_cn&edition=full","pubTime":"2025-10-21 20:31","pubTimestamp":1761049870,"startTime":"0","endTime":"0","summary":"Fortress Biotech及其子公司Urica Therapeutics宣布，Crystalys Therapeutics正在进行的全球III期Dotinurad治疗痛风的临床试验首位患者已完成用药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIO","BK4139"],"gpt_icon":0},{"id":"1158296044","title":"Fortress Biotech Inc.及其子公司Urica Therapeutics宣布Crystalys Therapeutics完成2.05亿美元A轮融资","url":"https://stock-news.laohu8.com/highlight/detail?id=1158296044","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158296044?lang=zh_cn&edition=full","pubTime":"2025-10-01 20:06","pubTimestamp":1759320378,"startTime":"0","endTime":"0","summary":"Fortress Biotech Inc.及其子公司Urica Therapeutics宣布Crystalys Therapeutics完成2.05亿美元A轮融资","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIO","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fortressbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0769},{"period":"1month","weight":-0.2225},{"period":"3month","weight":-0.262},{"period":"6month","weight":-0.2941},{"period":"1year","weight":0.5954},{"period":"ytd","weight":-0.2459}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Fortress Biotech, Inc.于2006年6月28日在特拉华州注册成立。该公司是一家生物制药公司，专注于收购和推进资产，通过产品收入、股权持有以及股息和特许权使用费收入流为股东提升长期价值。","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":0.066033},{"month":2,"riseRate":0.636364,"avgChangeRate":0.019184},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.026122},{"month":4,"riseRate":0.4,"avgChangeRate":-0.006403},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.025034},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.018965},{"month":7,"riseRate":0.545455,"avgChangeRate":-0.008162},{"month":8,"riseRate":0.545455,"avgChangeRate":0.05815},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.057104},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.163485},{"month":11,"riseRate":0.818182,"avgChangeRate":0.114632},{"month":12,"riseRate":0.545455,"avgChangeRate":0.07644}],"exchange":"NASDAQ","name":"Fortress Biotech Inc.","nameEN":"Fortress Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fortress Biotech Inc.(FBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Fortress Biotech Inc.(FBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Fortress Biotech Inc.,FBIO,Fortress Biotech Inc.股票,Fortress Biotech Inc.股票老虎,Fortress Biotech Inc.股票老虎国际,Fortress Biotech Inc.行情,Fortress Biotech Inc.股票行情,Fortress Biotech Inc.股价,Fortress Biotech Inc.股市,Fortress Biotech Inc.股票价格,Fortress Biotech Inc.股票交易,Fortress Biotech Inc.股票购买,Fortress Biotech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fortress Biotech Inc.(FBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Fortress Biotech Inc.(FBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}